Business Context and Reporting Period
This Form 8-K is filed by Neuralstem, Inc. (not Palisade Bio, Inc.) on May 15, 2009. The report discloses the Company's results of operations and financial condition for the three-month period ended March 31, 2009, referencing a press release attached as Exhibit 99.1.
Key Financial Metrics
The filing text provided does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the referenced press release (Exhibit 99.1), which is incorporated by reference but not included in the input text.
Material Changes
The filing does not explicitly detail material changes versus the prior comparable period within the text provided. It serves solely as a notification that the Q1 2009 results have been announced via a press release.
Guidance, Outlook, and Risks
The document includes standard Regulation FD disclosure language. It states that the information is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that section. No specific guidance, outlook, or risk factors are detailed in the text of this 8-K form itself.
Investor Verification Checklist
- Verify the specific financial figures (revenue, net loss, cash position) in the attached Exhibit 99.1 Press Release.
- Confirm the Company name is Neuralstem, Inc., as the input metadata incorrectly listed "Palisade Bio, Inc."
- Review the full press release for any operational updates or clinical trial milestones not summarized in this 8-K.
- Check subsequent filings for any restatements or updates to the March 31, 2009 results.